Format

Send to

Choose Destination
Clin Infect Dis. 2014 Sep 1;59(5):676-81. doi: 10.1093/cid/ciu397. Epub 2014 May 30.

Lyme disease testing by large commercial laboratories in the United States.

Author information

1
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado.
2
Connecticut Emerging Infections Program, Department of Biological and Environmental Sciences, Western Connecticut State University, Danbury.
3
Connecticut Emerging Infections Program, Yale School of Public Health, New Haven.
4
Minnesota Department of Health, St Paul.
5
Maryland Department of Health and Mental Hygiene, Baltimore.
6
New York State Department of Health, Albany.

Abstract

BACKGROUND:

Laboratory testing is helpful when evaluating patients with suspected Lyme disease (LD). A 2-tiered antibody testing approach is recommended, but single-tier and nonvalidated tests are also used. We conducted a survey of large commercial laboratories in the United States to assess laboratory practices. We used these data to estimate the cost of testing and number of infections among patients from whom specimens were submitted.

METHODS:

Large commercial laboratories were asked to report the type and volume of testing conducted nationwide in 2008, as well as the percentage of positive tests for 4 LD-endemic states. The total direct cost of testing was calculated for each test type. These data and test-specific performance parameters available in published literature were used to estimate the number of infections among source patients.

RESULTS:

Seven participating laboratories performed approximately 3.4 million LD tests on approximately 2.4 million specimens nationwide at an estimated cost of $492 million. Two-tiered testing accounted for at least 62% of assays performed; alternative testing accounted for <3% of assays. The estimated frequency of infection among patients from whom specimens were submitted ranged from 10% to 18.5%. Applied to the total numbers of specimens, this yielded an estimated 240 000 to 444 000 infected source patients in 2008.

DISCUSSION:

LD testing is common and costly, with most testing in accordance with diagnostic recommendations. These results highlight the importance of considering clinical and exposure history when interpreting laboratory results for diagnostic and surveillance purposes.

KEYWORDS:

United States; cost; diagnostic testing; infection; lyme disease

PMID:
24879782
PMCID:
PMC4646413
DOI:
10.1093/cid/ciu397
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center